Notably, the primary therapeutic strategy for NAFLD is targeting intrahepatic lipid accumulation, such as the agonists of FAO including peroxisome proliferator-activated receptor alpha (PPARα) agonists, acyl-coenzyme A oxidase 1 (Acox1) agonists and inhibitors of de novo lipogenesis including fatty acid synthase (FASN) inhibitors. The gene discussed is PPARA; the disease is metabolic dysfunction-associated steatotic liver disease.